Mitsuo Numata

This inventor holds 21 USPTO granted patents, primarily in Cephalosporin Chemistry. Top assignees: Takeda Chemical Industries, Inc., Tatsuo Chemical Ind., Ltd.. Active years: 1976-1992.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mitsuo Numata. Retrieved from https://idiyas.com/inventor/mitsuo-numata

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21

% Patents Active = 100.0

Average Co-Inventor Count = 3.5

ph-index = 6

Forward Citations = 144(Granted Patents)

Location History:

Takatsuki, JA (1976 - 1978)
Osaka, JA (1977 - 1978)
Osaka, JP (1979 - 1989)
Takatsuki, JP (1980 - 1992)

Company Filing History:

20 out of 1,858

Takeda Chemical Industries, Inc.

patents

1 out of 1

Tatsuo Chemical Ind., Ltd.

patent

Years Active: 1976-1992

Loading Chart...

Areas of Expertise:

Cephalosporin Derivatives

Cephalosporin Esters

Acyloxyalkyl Esters

Thiazolyl Compounds

Antibiotic Production

6-Aminopenicillanic Acid

Cephem Compounds

Lactol-Type Cephalosporins

Morpholino Compounds

Thio-Acetamido

Oxoimino Acetamido

Production Processes

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5120841 - Cephalosporin ester derivatives (1992-06-09),

2. 4963542 - Cephalosporin derivatives (1990-10-16),

3. 4797395 - 1-Acyloxyalkyl esters of cephalosporin (1989-01-10),

4. 4755598 - 1 (1988-07-05),

5. 4729992 - Cephalosporin esters, their production and use (1988-03-08),

6. 4725592 - 1-Acyloxyalkyl esters of cephalosporin (1988-02-16),

7. 4517361 - Cephalosporin derivatives (1985-05-14),

8. 4427586 - 2-Oxoazetidine derivatives and production thereof (1984-01-24),

9. 4421912 - Cephalosporin derivatives (1983-12-20),

10. 4379924 - Cephalosporin derivatives (1983-04-12),

11. 4264595 - 7-[2-(2-Imino-4-thiazolin (1981-04-28),

12. 4239758 - Cephalosporins (1980-12-16),

13. 4238608 - 7-[2-(2-Aminothiazol-4-yl)-2-substituted thio-acetamido] cephalosporins (1980-12-09),

14. 4200575 - 7[(2-Thiazolyl)-2-(oxoimino)acetamido]cephalosporin derivatives (1980-04-29),

15. 4172891 - Cephalosporins (1979-10-30),

Title: Innovations of Mitsuo Numata: A Pioneer in Antibiotic Development

Introduction

Mitsuo Numata, an esteemed inventor based in Osaka, Japan, has made significant contributions to the field of antibiotic research and development. With a remarkable portfolio of 21 patents, his work has focused on cephalosporin derivatives, advancing the efficacy and delivery of pharmaceutical compounds that play a crucial role in combating bacterial infections.

Latest Patents

Numata’s most recent patents include an innovative class of cephalosporin ester derivatives. These compounds, characterized by specific molecular formulas, exhibit improved absorbability, allowing for effective oral application as antibiotics. Additionally, he has developed a series of cephalosporin derivatives, notably 2-(syn)-hydroxyimino-acetamide derivatives, which are positioned as valuable antibacterial agents. These advancements underscore his commitment to enhancing pharmaceutical compositions and processes for their production.

Career Highlights

Throughout his career, Mitsuo Numata has been associated with leading pharmaceutical companies, including Takeda Chemical Industries, Inc. and Tatsuo Chemical Industries, Ltd. His expertise and innovative approach have positioned him as a key player in the development of new antibiotic solutions, contributing significantly to the scientific community.

Collaborations

Numata has collaborated with prominent figures such as Masayoshi Yamaoka and Isao Minamida. These partnerships have facilitated the exchange of ideas and have been instrumental in driving forward innovative projects within the realm of antibiotic research.

Conclusion

Mitsuo Numata's contributions to the field of pharmaceuticals, particularly in antibiotic development, are profound. His extensive patent portfolio and collaborative efforts exemplify the spirit of innovation that drives progress in the medical community. As he continues to explore new avenues in research, his work remains a cornerstone for future advancements in treatment options for bacterial infections.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]